The next focusIR Investor Webinar takes places on 14th May with guest speakers from Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksItaconix Plc Regulatory News (ITX)

Share Price Information for Itaconix Plc (ITX)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 157.50
Bid: 150.00
Ask: 165.00
Change: 0.00 (0.00%)
Spread: 15.00 (10.00%)
Open: 0.00
High: 0.00
Low: 0.00
Prev. Close: 157.50
ITX Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Board Appointment

10 Jul 2012 08:09

RNS Number : 2592H
Revolymer PLC
10 July 2012
 



10 July 2012

Revolymer plc

("Revolymer" or "the Group")

Julian Heslop to Join the Board of Revolymer

 

Former CFO of GSK to become an Independent Non-Executive Director

 

Revolymer, the British polymer company developing products for a number of high value fast moving consumer goods ("FMCG") markets, is pleased to announce that, as a consequence of the Group's admission to the AIM Market today, the appointment of Julian Heslop to the Board has now become effective.

 

Julian served as Chief Financial Officer of GlaxoSmithKline plc ("GSK") between April 2005 and March 2011. He was also Chairman of ViiV Healthcare Limited until March 2011. He served as Senior Vice President, Operations Controller of GSK between January 2001 and March 2005 and as Financial Controller of Glaxo Wellcome plc from April 1998 to December 2000. Prior to this, Julian had senior finance roles at Grand Metropolitan plc and Imperial Brewing and Leisure. He is a Fellow of the Institute of Chartered Accountants in England and Wales.

 

Julian Heslop, commenting on his appointment said, "I am delighted to be joining the Board of Revolymer. I look forward to playing an active role as the Group seeks to generate significant value from its broad product pipeline by signing a number of licensing deals with important players in the FMCG markets it is targeting."

 

Jack Keenan, Chairman of Revolymer commenting on today's announcement said, "Julian's decision to join the Board of Revolymer, upon its Admission to AIM, is an important endorsement of the Group's technology and the market opportunities that it has chosen to pursue. His financial knowledge and experience in both pharmaceutical and FMCG markets will be extremely valuable as the company seeks to develop its business."

 

Further information on Julian Spenser Heslop as required by AIM Rule 17 and Schedule Two, paragraph (g) of the AIM Rules for Companies is to be found in paragraph 4 of Part VI of the Group's Admission Document which was published on 4 July 2012 and available at www.revolymer.com

 

 

Ends

 

 

Revolymer plc

+44 (0) 1244 283 500

Roger Pettman

Rob Cridland

 

Panmure Gordon (UK) Limited

+44 (0) 20 7459 3600

Callum Stewart / Adam James (Corporate Finance)

Adam Pollock / Charles Leigh-Pemberton (Corporate Broking)

 

Citigate Dewe Rogerson

+44 (0)20 7638 9571

Ginny Pulbrook / David Dible

 

About Revolymer

 

Revolymer® is a technology company that designs, develops and formulates novel polymers to improve the performance of existing consumer products within the FMCG markets. Revolymer's strategy is to generate significant and growing revenue streams by licensing its unique and proprietary technologies to manufacturers and marketers within the global high value FMCG industry. Current applications for the Group's technologies are in the confectionery chewing gum and medicated chewing gum (together "gum") markets; and in coatings & adhesives, household products and personal care (together "consumer specialties").

www.revolymer.com

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
BOARLMATMBAMBTT
Date   Source Headline
29th Apr 20247:00 amRNSLaunch of two plant-based performance ingredients
19th Apr 20247:00 amRNSGrants of Options & PDMR dealings
15th Apr 20247:00 amRNSPreliminary Results and Notice of AGM
8th Apr 20247:00 amRNSNotice of Results
2nd Apr 20247:00 amRNSTrading Statement
27th Feb 20247:00 amRNSTrading Update
9th Feb 20247:00 amRNSAppointment of Non-Executive Director
26th Jan 20247:00 amRNSAppointment: Nominated Adviser and Sole Broker
15th Dec 20237:00 amRNSDirector/PDMR Shareholding
15th Dec 20237:00 amRNSDirector/PDMR Shareholding
7th Dec 20237:00 amRNSTrading Update
30th Oct 20237:00 amRNSDirector/PDMR Shareholding
26th Oct 20235:28 pmRNSDirector/PDMR Shareholding
19th Oct 20235:08 pmRNSDirector/PDMR Shareholding
19th Oct 20237:00 amRNSDirector/PDMR Shareholding
5th Oct 202311:01 amRNSHoldings in Company
12th Sep 20237:00 amRNSHalf year results
5th Sep 20237:00 amRNSNotice of Interim Results and Presentations
22nd Aug 20237:00 amRNSShare Consolidation & Total Voting Rights
15th Aug 20237:00 amRNSShare Consolidation
12th Jul 20237:00 amRNSTrading Update
28th Jun 202312:29 pmRNSAGM Statement
5th Jun 20237:00 amRNSFinal Results
24th May 20237:00 amRNSNotice of Final Results, Briefings, and AGM
25th Apr 20237:00 amRNSAppointment of Joint Corporate Broker
2nd Mar 20233:25 pmRNSTR-1
1st Mar 20237:00 amRNSAward from Frost & Sullivan
28th Feb 20236:03 pmRNSTR-1
28th Feb 20235:04 pmRNSTR-1
28th Feb 20233:09 pmRNSTR-1
23rd Feb 20237:00 amRNSTR-1
22nd Feb 202312:28 pmRNSResults of Open Offer, GM and Total Voting Rights
15th Feb 20237:00 amRNSInvestor Presentation following GM on 22 Feb 2023
3rd Feb 20237:00 amRNSPlacing, Subscription and Open Offer; Notice of GM
5th Jan 20237:00 amRNSBoard Change
6th Dec 20224:40 pmRNSSecond Price Monitoring Extn
6th Dec 20224:35 pmRNSPrice Monitoring Extension
5th Oct 20227:00 amRNSItaconix and Brenntag Promote Sustainable Cleaning
14th Sep 20227:00 amRNSHalf year results
13th Sep 202211:05 amRNSSecond Price Monitoring Extn
13th Sep 202211:00 amRNSPrice Monitoring Extension
7th Sep 20227:00 amRNSNotice of Results
5th Sep 20227:00 amRNSItaconix and Croda Renew Supply Agreement
20th Jul 20227:00 amRNSBoard Change
13th Jul 20227:00 amRNSTrading Update
5th Jul 20227:00 amRNSDirectorate Change
1st Jul 20222:37 pmRNSResult of AGM
1st Jul 20229:00 amRNSPrice Monitoring Extension
1st Jul 20227:00 amRNSAGM Statement and Notice of Capital Markets Event
29th Jun 20227:00 amRNSNotice of Capital Markets Webinar

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.